Retraction Note: Regulation of miRNAs on c-met protein expression in ovarian cancer and its implication.

The article "Regulation of miRNAs on c-met protein expression in ovarian cancer and its implication", by H. Liu, S.-R. Li, Q. Si, published in Eur Rev Med Pharmacol Sci 2017; 21 (15): 3353-3359-PMID: 28829508 has been retracted by the Editor in Chief. Following some concerns raised on PubPeer regarding a possible manipulation in Figure 5 (link: https://pubpeer.com/publications/7B6E6E6679990661654EBCAF472921), the Editor in Chief has started an investigation to assess the validity of the results as well as possible figure manipulation. The authors were informed about the journal's investigation but remained unresponsive and have not provided the manuscript's raw data. The journal's investigation revealed a figure overlap between panels pcDNA3.1-EGFP and pcDNA3.1-EGFP-204-up in Figure 5. Consequently, the Editor in Chief mistrusts the results presented and has decided to retract the article. This article has been retracted. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/13200.

[Related factors of acute symptomatic seizures and epilepsy in children with myelin oligodendrocyte glycoprotein antibody-associated disease].

Objective: To investigate the risk factors of acute symptomatic seizures (ASS) and epilepsy in children with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Methods: A ambispective cohort study was used including 74 children with MOGAD who were admitted to the Department of Pediatrics of Peking University First Hospital from January 2013 to June 2023 and were followed up. Demographic information, clinical information, treatment status, ASS and epilepsy status were collected. The clinical phenotypes were classified. According to the presence or absence of ASS in the course of disease, the children and the course of disease were divided into groups with and without ASS. Chi-square test, Fisher exact test and Mann Whitney U test were used to analyze the correlation between symptoms and auxiliary examination characteristics and the occurrence of ASS in the two groups of children. Multivariate Logistic regression analysis was used for multivariate analysis. Results: The onset age of the 74 children with MOGAD was 6.58 (3.80, 9.67) years, including 38 females (51.4%) and 36 males (48.6%). The duration of the final follow-up was 2.67 (1.10, 4.12) years, with a total of 239 times acute clinical episodes. ASS occurred in 39.2% (29/74) children during the course of disease and in 29.3% (70/239) of attacks. The common phenotypes were ADEM (67 times (28.0%)), optic neuritis (37 times (15.4%)) and cerebral cortical encephalitis (31 times (13.0%)) in 239 times acute clinical episodes. The incidence of ASS in ADEM and cerebral cortical encephalitis phenotype was 28.4%(19/67) and 100.0% (31/31), respectively. Multivariate analysis showed that cortical involvement on magnetic resonance imaging during clinical attacks was an independent risk factor for ASS (ß=-1.49, OR=0.23) after excluding attacks involving only optic nerve or spinal cord (49 episodes). During the follow-up, 5 children (6.8%) had epilepsy, and all children with epilepsy had multiple clinical attacks of MOGAD and previous ASS. Conclusions: Cortical involvement on magnetic resonance imaging during clinical episodes is an independent risk factor for ASS in children with MOGAD. All MOGAD children with epilepsy had ASS and multiple MOGAD clinical episodes in the past.

Restriction site polymorphisms at the human HepG2 glucose transporter gene locu in Caucasian and West Indian subjects with non-insulin-dependent diabetes mellitus

Digestion of human genomic DNA with the restriction enzyme Stul revealed a 2-allele polymorphism with a human HepG2 glucose transporter probe. Bands of 3.2 kilobases (kb; SI allele) and 2.6 kb (S2 allele) were observed. The genotype frequencies were investigated in 2 non-insulin-dependent diabetic populations. The gene type frequencies of S1S1, S1S2 and S2S2 were 6, 42 and 52 percent among Caucasian diabetic subjects (n=48), and 11, 38 and 51 percent in 47 controls, respectively. In West Indian diabetic patients (n=48), the genotype frequencies were 17, 54 and 29 percent, and for 36 controls they were 25, 33 and 42 percent, respectively. The polymorphism information content of this restriction fragment length polymorphism (RFLP) is 0.32 in Caucasians and 0.37 in West Indians, respectively. There was no significant difference of allele or genotype frequencies between the diabetic patients and non-diabetic controls in either group. Haple type analysis of Stul and Xbal RFPLs showed that there was also no significant difference in the frequencies of the four different haplotypes S1X1, S1X2, S2X1 and S2X2 between the patients and controls. However there was a difference for the frequency of the S1 allele between Caucasians (control 30 percent, patients 27 percent) and West Indians (controls 42 percent, patients 44 percent). There was also a significant difference in the frequency of haplotype S2X2 between these two racial groups (controls 48 percent, cases 51 percent for Caucasians, and controls 33 percent, cases 22 percent for West Indians). (AU)